CYTH

Cyclo Therapeutics, Inc. [CYTH] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CYTH Stock Summary

Top 10 Correlated ETFs

CYTH


Top 10 Correlated Stocks

CYTH


In the News

08:05 28 Mar 2024 CYTH

Cyclo Therapeutics to Present at 8th Annual Dawson James Conference

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer and Joshua Fine, Chief Financial Officer of Cyclo Therapeutics will present at the 8th Annual Dawson James Conference being held in Jupiter, FL on Thursday,.

08:05 28 Mar 2024 CYTH

Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

GAINESVILLE, Fla.--( BUSINESS WIRE )--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023 at 11:00 AM ET.

08:05 28 Mar 2024 CYTH

Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-

08:05 28 Mar 2024 CYTH

Cyclo Therapeutics to Present at the China NPC Association Meeting

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Lise Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will present at the 2022 China Nieman Pick Medical Exchange & Sixth Patient Association being held August 13, 2022 in Xiamen,

08:05 28 Mar 2024 CYTH

Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it will participate at the 30th Annual NNPDF Family Support & Medical Conference in conjunction with the INPDA Biennial Meeting being held July 28-31, 2022, in Orlando, FL. “Perspectives from

08:05 28 Mar 2024 CYTH

Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Lise Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will present at the World Orphan Drug Congress USA 2022 being held July 11-13, 2022 in Boston, MA. During the session, Dr. Kjems w

08:05 28 Mar 2024 CYTH

Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Professor Caroline Hastings, MD will present at the 2022 NPC Conference hosted by the Australian NPC Disease Foundation being held virtually June 23-24, 2022. Details of the presentation are as f

08:05 28 Mar 2024 CYTH

Cyclo Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 PM ET. In addition to the presentation, ma

08:05 28 Mar 2024 CYTH

Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the poster presentation of its ongoing pivotal Phase 3 study, TransportNPC™ at the 18th Annual WORLDSymposium 2022, a leading medical and scientific conference for professionals working to advance und

08:05 28 Mar 2024 CYTH

Cyclo Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Virtual Investor 2022 Top Picks Conference on Thursday, January 27, 2022 at 10:00 AM ET. As part of the virtual ev

CYTH Financial details

Company Rating
Neutral
Market Cap
42.79M
Income
-20.06M
Revenue
1.08M
Book val./share
0.19
Cash/share
0.37
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-1.25
Forward P/E
-2.92
PEG
0.28
P/S
35.64
P/B
-22.92
P/C
3.78
P/FCF
-2.32
Quick Ratio
0.32
Current Ratio
0.83
Debt / Equity
0.22
LT Debt / Equity
0
-
-
EPS (TTM)
-1.31
EPS next Y
-0.48
EPS next Q
-0.17
EPS this Y
-48.75%
EPS next Y
-63.36%
EPS next 5Y
-202.29%
EPS last 5Y
-27.89%
Revenue last 5Y
1.34%
Revenue Q/Q
-37.15%
EPS Q/Q
-20.69%
-
-
-
-
SMA20
-50%
SMA50
-50%
SMA100
-
Inst Own
15.33%
Inst Trans
-4.87%
ROA
-343%
ROE
3430%
ROC
18.9%
Gross Margin
91%
Oper. Margin
-2036%
Profit Margin
-2020%
Payout
-
Shs Outstand
28.72M
Shs Float
12.63M
-
-
-
-
Target Price
-
52W Range
0.67-2.57
52W High
-
52W Low
-
RSI
37
Rel Volume
0.21
Avg Volume
118.49K
Volume
24.97K
Perf Week
-2.1%
Perf Month
-16.17%
Perf Quarter
17.65%
Perf Half Y
-3.45%
-
-
-
-
Beta
-0.139
-
-
Volatility
0.03%, 0.11%
Prev Close
0%
Price
1.4
Change
0.72%

CYTH Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.830.560.250.220.07
Net income per share
-6.31-5.58-2.25-2.4-1.23
Operating cash flow per share
-5.42-5.34-2.36-2.37-0.99
Free cash flow per share
-5.42-5.37-2.36-2.38-0.99
Cash per share
2.298.032.610.240.57
Book value per share
0.776.542.460.120.29
Tangible book value per share
0.776.542.460.120.29
Share holders equity per share
0.776.542.460.120.29
Interest debt per share
0.040.120.03-0.020.06
Market cap
41.33M6.96M23.76M9.04M25.96M
Enterprise value
38.6M-5.7M7.32M7.5M17.75M
P/E ratio
-5.39-0.78-1.66-0.59-1.29
Price to sales ratio
41.047.714.986.5724.12
POCF ratio
-6.27-0.81-1.58-0.6-1.6
PFCF ratio
-6.27-0.81-1.58-0.6-1.6
P/B Ratio
44.160.671.5212.315.46
PTB ratio
44.160.671.5212.315.46
EV to sales
38.32-6.34.625.4516.49
Enterprise value over EBITDA
-5.330.64-0.51-0.48-0.89
EV to operating cash flow
-5.860.67-0.49-0.5-1.1
EV to free cash flow
-5.860.66-0.49-0.5-1.1
Earnings yield
-0.19-1.28-0.6-1.69-0.77
Free cash flow yield
-0.16-1.24-0.63-1.67-0.62
Debt to equity
0.060.020.0100.22
Debt to assets
0.010.010.0100.08
Net debt to EBITDA
0.381.411.160.10.41
Current ratio
1.263.835.071.191.45
Interest coverage
000103.760
Income quality
0.870.961.050.980.81
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
3.414.074.15.675.26
Research and developement to revenue
4.836.755.776.5413.18
Intangibles to total assets
00000
Capex to operating cash flow
00.01000
Capex to revenue
0-0.06-0.01-0.010
Capex to depreciation
-0.23-4.16-1.34-0.77-0.13
Stock based compensation to revenue
0.430.30.30.370.68
Graham number
10.4628.6511.152.52.84
ROIC
-7.23-0.84-0.9-21.02-3.45
Return on tangible assets
-1.87-0.63-0.73-3.62-1.51
Graham Net
-0.115.822.09-0.280.06
Working capital
816.95K10.38M15.61M677.89K3.85M
Tangible asset value
935.98K10.45M15.67M734.54K4.76M
Net current asset value
780.82K10.31M15.59M677.89K3.83M
Invested capital
0.060.020.0100.22
Average receivables
149.99K147.14K325.44K297.04K88.69K
Average payables
2.53M3.33M3.61M3.58M4.17M
Average inventory
329.58K240.27K232.67K240.96K254.42K
Days sales outstanding
66.1345.17124.0814.5941.5
Days payables outstanding
15.11K19.47K8.6K9.14K508.42
Days of inventory on hand
1.17K1.31K531.87668.6126.63
Receivables turnover
5.528.082.9425.028.8
Payables turnover
0.020.020.040.040.72
Inventory turnover
0.310.280.690.5513.71
ROE
-8.2-0.85-0.91-20.8-4.22
Capex per share
0-0.03000

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.030.010.010.030.01
Net income per share
-0.76-0.46-0.33-0.29-0.23
Operating cash flow per share
-0.43-0.4-0.25-0.25-0.17
Free cash flow per share
-0.43-0.4-0.25-0.25-0.17
Cash per share
0.240.080.060.110.37
Book value per share
0.12-0.04-0.11-0.070.19
Tangible book value per share
0.12-0.04-0.11-0.070.19
Share holders equity per share
0.12-0.04-0.11-0.070.19
Interest debt per share
0.030000.04
Market cap
9.04M9.24M22.33M22.99M39.54M
Enterprise value
7.5M8.38M21.53M21.24M31.33M
P/E ratio
-0.47-0.46-1.2-1.2-1.75
Price to sales ratio
48.4160.65190.6446.4126.98
POCF ratio
-3.29-2.11-6.42-5.69-9.21
PFCF ratio
-3.31-2.11-6.42-5.69-9.2
P/B Ratio
12.31-21.06-15.04-21.848.31
PTB ratio
12.31-21.06-15.04-21.848.31
EV to sales
40.1454.99183.8742.86100.61
Enterprise value over EBITDA
-1.51-1.68-4.66-4.46-5.56
EV to operating cash flow
-2.73-1.92-6.19-5.25-7.29
EV to free cash flow
-2.75-1.92-6.19-5.25-7.29
Earnings yield
-0.53-0.54-0.21-0.21-0.14
Free cash flow yield
-0.3-0.47-0.16-0.18-0.11
Debt to equity
0-0.12-0.03-0.040.22
Debt to assets
00.010.010.010.08
Net debt to EBITDA
0.310.170.170.371.46
Current ratio
1.190.890.750.831.45
Interest coverage
-26.88106.53K000
Income quality
0.550.870.750.850.76
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
10.4511.4410.883.084.49
Research and developement to revenue
17.0522.327.07713.31
Intangibles to total assets
00000
Capex to operating cash flow
-0.010000
Capex to revenue
0.08000-0.01
Capex to depreciation
3.1000-0.5
Stock based compensation to revenue
1.150.61.580.410.83
Graham number
1.40.640.890.660.99
ROIC
-6.5415.093.354.96-0.97
Return on tangible assets
-1.14-1.22-1-0.85-0.43
Graham Net
-0.28-0.31-0.36-0.280.04
Working capital
677.89K-506.11K-1.55M-1.11M3.85M
Tangible asset value
734.54K-438.88K-1.48M-1.05M4.76M
Net current asset value
677.89K-542.64K-1.58M-1.14M3.83M
Invested capital
0-0.12-0.03-0.040.22
Average receivables
224.78K93.11K109.81K196.08K213.07K
Average payables
3.18M3.98M5.28M6.34M5.73M
Average inventory
262.81K249.49K240.57K223.2K232.05K
Days sales outstanding
26.4977.4967.9255.1835.37
Days payables outstanding
19.87K39.57K27.48K15.33K498.64
Days of inventory on hand
1.45K2.16K1.07K486.9626.12
Receivables turnover
3.41.161.321.632.54
Payables turnover
0000.010.18
Inventory turnover
0.060.040.080.183.45
ROE
-6.5511.413.124.53-1.19
Capex per share
00000

CYTH Frequently Asked Questions

What is Cyclo Therapeutics, Inc. stock symbol ?

Cyclo Therapeutics, Inc. is a US stock , located in Gainesville of Fl and trading under the symbol CYTH

What is Cyclo Therapeutics, Inc. stock quote today ?

Cyclo Therapeutics, Inc. stock price is $1.4 today.

Is Cyclo Therapeutics, Inc. stock public?

Yes, Cyclo Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap